MX356279B - Métodos para el tratamiento de soriasis usando antagonistas de il-17. - Google Patents

Métodos para el tratamiento de soriasis usando antagonistas de il-17.

Info

Publication number
MX356279B
MX356279B MX2013003916A MX2013003916A MX356279B MX 356279 B MX356279 B MX 356279B MX 2013003916 A MX2013003916 A MX 2013003916A MX 2013003916 A MX2013003916 A MX 2013003916A MX 356279 B MX356279 B MX 356279B
Authority
MX
Mexico
Prior art keywords
treating psoriasis
antagonists
methods
antibody
binding molecule
Prior art date
Application number
MX2013003916A
Other languages
English (en)
Other versions
MX2013003916A (es
Inventor
Guettner Achim
Machacek Matthias
Papavassilis Charis
Sander Oliver
Original Assignee
Novartis Ag Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356279(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag Star filed Critical Novartis Ag Star
Publication of MX2013003916A publication Critical patent/MX2013003916A/es
Publication of MX356279B publication Critical patent/MX356279B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a el uso de secukinumab en la preparación de un medicamento para tratar psoriasis, en donde el secukinumab: a) está adaptado para ser administrable a un paciente que necesita del mismo durante un régimen de inducción, en donde el régimen de inducción comprende un régimen de carga, en donde el régimen de carga comprende cinco dosis subcutáneas de 150 mg a 300 mg de secukinumab, cada una de las cinco dosis semanalmente, empezando en la semana cero: y b) posteriormente, está adaptado para ser administrable durante un régimen de mantenimiento, en donde el régimen de mantenimiento comprende dosis subcutáneas de 150 mg a 300 mg de secukinumab cada cuatro semanas.
MX2013003916A 2010-10-08 2011-10-07 Métodos para el tratamiento de soriasis usando antagonistas de il-17. MX356279B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (2)

Publication Number Publication Date
MX2013003916A MX2013003916A (es) 2013-06-03
MX356279B true MX356279B (es) 2018-05-22

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003916A MX356279B (es) 2010-10-08 2011-10-07 Métodos para el tratamiento de soriasis usando antagonistas de il-17.

Country Status (28)

Country Link
US (9) US9717791B2 (es)
EP (5) EP3299390A1 (es)
JP (2) JP5537740B2 (es)
KR (3) KR20150018595A (es)
CN (2) CN107029234A (es)
AU (1) AU2011311482B2 (es)
BR (1) BR112013008501A2 (es)
CA (1) CA2813900C (es)
CL (1) CL2013000930A1 (es)
CY (1) CY1119942T1 (es)
DK (1) DK2625199T3 (es)
ES (1) ES2660770T3 (es)
HK (1) HK1247932A1 (es)
HR (1) HRP20180301T1 (es)
HU (1) HUE038334T2 (es)
IL (1) IL225310A (es)
LT (1) LT2625199T (es)
MA (1) MA34646B1 (es)
MX (1) MX356279B (es)
NO (1) NO2625199T3 (es)
PH (1) PH12013500660B1 (es)
PL (1) PL2625199T3 (es)
PT (1) PT2625199T (es)
RU (2) RU2591083C2 (es)
SG (1) SG188979A1 (es)
SI (1) SI2625199T1 (es)
TW (2) TWI564022B (es)
WO (1) WO2012045848A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2012341081B2 (en) * 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
EP3689369A1 (en) * 2013-03-15 2020-08-05 Amgen, Inc Methods for treating psoriasis using an anti-il-23 antibody
WO2014143540A1 (en) * 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
KR101836756B1 (ko) 2013-12-27 2018-03-08 오사카 유니버시티 Il-17a를 표적화하는 백신
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
MY184189A (en) * 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
CA2949236C (en) 2014-05-15 2023-06-13 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016031250A1 (en) * 2014-08-26 2016-03-03 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
SMT202400285T1 (it) * 2014-09-10 2024-09-16 Novartis Ag Uso di antagonisti di il-17 per inibire la progressione del danno strutturale in pazienti affetti da artrite psoriasica
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2978431C (en) 2015-03-02 2023-10-24 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
RU2754683C2 (ru) * 2015-10-27 2021-09-06 Юсб Биофарма Срл Способы лечения с использованием анти-il-17a антител
WO2018015880A1 (en) 2016-07-19 2018-01-25 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
WO2018096467A1 (en) * 2016-11-28 2018-05-31 Novartis Ag Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
EP4006053A4 (en) 2019-07-30 2022-10-26 Jiangsu Hengrui Medicine Co., Ltd. METHOD OF TREATMENT OF AUTOIMMUNE DISEASE BY IL-17 ANTAGONISTS
BR112022004941A2 (pt) 2019-09-20 2022-06-28 Novartis Ag Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250442A (en) 1993-04-08 1993-10-05 Orestes Cabezas Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja) 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
JP4159682B2 (ja) 1998-12-22 2008-10-01 株式会社クラレ 止血材
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US8039642B2 (en) 2003-12-09 2011-10-18 Life Technologies Corporation Pyrenyloxysulfonic acid fluorescent agents
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
LT2481753T (lt) * 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
RU2430110C2 (ru) 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
CN101932935A (zh) 2007-06-20 2010-12-29 先灵公司 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
US7720605B2 (en) 2007-06-22 2010-05-18 Weyerhaeuser Nr Company Identifying vegetation attributes from LiDAR data
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
US20090301682A1 (en) 2008-06-05 2009-12-10 Baker Hughes Incorporated Casting furnace method and apparatus
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR101318549B1 (ko) * 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
BRPI0921845A2 (pt) 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
US20110256130A1 (en) 2008-12-01 2011-10-20 Joshua Robert Schultz Methods of treating inflammatory disorders
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
PT2625199T (pt) 2010-10-08 2018-02-28 Novartis Ag Métodos de tratamento de psoríase usando antagonistas de il-17
BR112013011176A2 (pt) 2010-11-05 2020-09-01 Novartis Ag métodos de tratamento de artrite reumatoide usando antagonistas de il-17
AR084234A1 (es) 2010-12-13 2013-05-02 Novartis Ag Metodos predictivos y metodos para tratar artritis usando antagonistas de interleuquina 17 (il-17)
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
JP2015519311A (ja) 2012-04-20 2015-07-09 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて強直性脊椎炎を治療する方法
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
IL257723B2 (en) 2015-10-19 2023-04-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
US11280479B2 (en) 2017-10-18 2022-03-22 The Sloan Company Sign box light module

Also Published As

Publication number Publication date
JP2014114288A (ja) 2014-06-26
CA2813900C (en) 2017-01-10
PH12013500660A1 (en) 2013-05-20
US12551554B2 (en) 2026-02-17
KR20130110179A (ko) 2013-10-08
TW201630625A (zh) 2016-09-01
PL2625199T3 (pl) 2018-04-30
PT2625199T (pt) 2018-02-28
SG188979A1 (en) 2013-05-31
RU2591083C2 (ru) 2016-07-10
KR101620771B1 (ko) 2016-05-12
US20250161443A1 (en) 2025-05-22
HK1247932A1 (en) 2018-10-05
CL2013000930A1 (es) 2014-03-28
US20130202610A1 (en) 2013-08-08
NO2625199T3 (es) 2018-04-21
US20170304439A1 (en) 2017-10-26
KR20140097566A (ko) 2014-08-06
IL225310A0 (en) 2013-06-27
AU2011311482A1 (en) 2013-04-04
WO2012045848A1 (en) 2012-04-12
MA34646B1 (fr) 2013-11-02
US20200171147A1 (en) 2020-06-04
PH12013500660B1 (en) 2017-10-27
CY1119942T1 (el) 2018-12-12
EP4670788A2 (en) 2025-12-31
US20210162044A1 (en) 2021-06-03
LT2625199T (lt) 2018-03-12
DK2625199T3 (en) 2018-02-26
US9717791B2 (en) 2017-08-01
KR20150018595A (ko) 2015-02-23
IL225310A (en) 2016-10-31
US20210113688A1 (en) 2021-04-22
JP5537740B2 (ja) 2014-07-02
HUE038334T2 (hu) 2018-10-29
BR112013008501A2 (pt) 2016-08-16
MX2013003916A (es) 2013-06-03
JP2013543501A (ja) 2013-12-05
US20250161445A1 (en) 2025-05-22
EP3299390A1 (en) 2018-03-28
US20250161444A1 (en) 2025-05-22
EP4137514A1 (en) 2023-02-22
US20230321231A1 (en) 2023-10-12
EP2625199A1 (en) 2013-08-14
AU2011311482B2 (en) 2014-05-29
US11534490B2 (en) 2022-12-27
CA2813900A1 (en) 2012-04-12
CN107029234A (zh) 2017-08-11
US10583190B2 (en) 2020-03-10
EP3792281A1 (en) 2021-03-17
EP2625199B1 (en) 2017-11-22
RU2665954C1 (ru) 2018-09-05
TWI564022B (zh) 2017-01-01
TWI548419B (zh) 2016-09-11
CN103154031A (zh) 2013-06-12
RU2013120957A (ru) 2014-11-20
EP4670788A3 (en) 2026-03-18
HRP20180301T1 (hr) 2018-03-23
TW201216984A (en) 2012-05-01
SI2625199T1 (en) 2018-03-30
ES2660770T3 (es) 2018-03-26

Similar Documents

Publication Publication Date Title
PH12013500660B1 (en) Methods of treating psoriasis using il-17 antagonists
PH12013500890A1 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
CY1122278T1 (el) Αντι il-36r αντισωματα
PH12016500141A1 (en) Methods of treating sporadic inclusion body myositis
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PH12013500315A1 (en) Antibodies that bind myostatin, compositions and methods
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
PH12013500810B1 (en) Anti-il-23 antibodies
EA201391332A1 (ru) Лиганды опиоидных рецепторов и способы их применения и получения
IN2014CN04160A (es)
WO2012103360A3 (en) Wnt compositions and methods of use thereof
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
UA106529C2 (uk) Гуманізоване антитіло до cxcr4 для лікування раку
UA107596C2 (uk) Виділений поліпептид, який зв'язується з рецептором інсуліноподібного фактора росту 1
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
TN2013000145A1 (en) Methods of treating psoriasis using il-17 antagonists
WO2012158493A3 (en) Compounds that bind to the erythropoietin receptor
TN2013000144A1 (en) Methods of treating rheumatoid arthuritis using il-17 antagonists
PH12014500934A1 (en) Nicotinic receptor non-competitive modulators
PH12013501453A1 (en) Nicotinic receptor non-competitive antagonists
TN2013000040A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
TN2013000186A1 (en) Anti-il-23 antibodies
NZ768582A (en) Antibodies and uses thereof to detect folate receptor 1

Legal Events

Date Code Title Description
FG Grant or registration